This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Implant containing 10.8 mg goserelin.

Drugs List

  • goserelin 10.8mg implant
  • ZOLADEX LA 10.8mg implant
  • Therapeutic Indications


    Carcinoma - prostate (if suitable for hormonal manipulation)

    Unlicensed Uses

    Gonadotrophin-dependent precocious puberty



    Inject one 10.8 mg implant every 12 weeks.


    Gonadotrophin-dependent precocious puberty (unlicensed)
    Inject one 10.8 mg implant every 12 weeks.


    The implant is injected subcutaneously into the anterior abdominal wall.

    Prior to administration the instruction card must be read.

    Rotate the injection site to prevent atrophy and nodule formation.



    Precautions and Warnings

    Children under 18 years
    Chronic use of drugs that cause osteoporosis
    Family history of long QT syndrome
    Strong family history of osteoporosis
    Tobacco smoking
    Underweight patients
    Chronic alcoholism
    Diabetes mellitus
    History of torsade de pointes
    Long QT syndrome
    Metabolic bone disease

    Prostate cancer: Prophylaxis of flare with anti-androgen is recommended
    Treatment to be initiated and supervised by a specialist
    If spinal cord compression present/develops,use specific standard treatment
    Monitor closely men at risk of tumour flare for first month of treatment
    Monitor closely patient with depression
    Monitor ECG in patients at risk of QT prolongation
    Monitor for signs and symptoms of glucose intolerance
    Monitor patients at risk of spinal cord compression or urinary obstruction
    Monitor patients with pre-existing hypertension
    Disease flare may occur at beginning of treatment
    If ureteric obstruction present/develops,use specific standard treatment
    May cause loss of bone mineral density
    Not licensed for use in children under 18 years

    Consideration should be given to the initial use of an anti-androgen (e.g. cyproterone acetate 300 mg daily for three days before and three weeks after commencement of goserelin) at the start of LHRH analogue therapy since this has been reported to prevent the possible sequelae of the initial rise in serum testosterone, which may be associated with the progression of prostate cancer.

    The use of LHRH agonists may cause a reduction in bone mineral density. Therefore, goserelin should be used with caution when treating patients with metabolic bone disease. Bone mineral density should be monitored.

    Concurrent use of a bisphosphonate may reduce bone mineral loss.

    Patients with injection site injury should be monitored for signs and symptoms of abdominal haemorrhage. Caution should be used when administering to patients with a low BMI and/or patients receiving anticoagulants.

    Pregnancy and Lactation


    Goserelin 10.8 mg implant is not indicated for use in women.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Goserelin 10.8 mg implant is not indicated for use in women.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal discomfort
    Blood dyscrasias
    Bone pain
    Breast swelling
    Breast tenderness
    Bruising at injection site
    Cardiac failure
    Changes in scalp or body hair
    Decrease in bone mineral density
    Decreased glucose tolerance
    Dry skin
    Erectile dysfunction
    Exacerbation of symptoms
    Gastro-intestinal disturbances
    Hair loss
    Hepatic disorders
    Hypersensitivity reactions
    Increase in serum cholesterol (transient)
    Increased bone pain (temporary)
    Increased sweating
    Injection site reactions
    Interstitial pneumonia
    Leg cramps
    Mood changes
    Myocardial infarction
    Peripheral oedema
    Pituitary adenomas
    Pituitary apoplexy
    Prolongation of QT interval
    Psychotic disorder
    Pulmonary embolism
    Reduced libido
    Sexual dysfunction
    Sleep disturbances
    Spinal cord compression
    Testicular atrophy
    Tumour flare
    Tumour pain
    Ureteric obstruction
    Visual disturbances
    Voice changes
    Weight changes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: April 2014

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Zoladex LA 10.8mg. AstraZeneca UK Ltd. Revised June 2015.

    NICE Evidence Services Available at: Last accessed: 07 September 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.